Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

2001
type: Class

Generically Dependent Continuant
type: Class

individual
type: Document
rights: termsOfUse
date: 2026-08-16T09:21:59
publisher: Effect of glycoprotein IIb/IIIa receptor blocker abcximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the Gusto IV-ACS randomised trial.
label: RDF description of Effect of glycoprotein IIb/IIIa receptor blocker abcximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the Gusto IV-ACS randomised trial. - http://research.umh.es/vivo/pub/articulo/5584

Effect of glycoprotein IIb/IIIa receptor blocker abcximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the Gusto IV-ACS randomised trial.
type: Document
ARG_2000028: 5584 vcard
has publication venue: LANCET
most specific type: Academic Article
type: 2001
date time value: 5584 pubdate
type: Generically Dependent Continuant
type: Information Content Entity
type: Entity
type: Thing
most specific type: 2001
related by: Autor:5562-Artículo:5584
type: Anualidad
type: Article
type: Academic Article
type: Continuant
page end: 1924
page start: 1915

LANCET
type: Journal
type: Entity
type: Generically Dependent Continuant
publication venue for: Effect of glycoprotein IIb/IIIa receptor blocker abcximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the Gusto IV-ACS randomised trial.
type: Information Content Entity
type: Periodical
type: Collection
type: Continuant
type: Thing

Autor:5562-Artículo:5584
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Effect of glycoprotein IIb/IIIa receptor blocker abcximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the Gusto IV-ACS randomised trial.